TABLE 2.

Antitumor Activity Outcomes

Outcome	Liposomal Irinotecan (n = 229)	Topotecan (n = 232)
Best overall response, No. (%)
Complete response	12 (5.2)	7 (3.0)
Partial response	89 (38.9)	43 (18.5)
Stable disease	68 (29.7)	98 (42.2)
Progressive disease	28 (12.2)	50 (21.6)
Not evaluable	29 (12.7)	32 (13.8)
Undefined	3 (1.3)	2 (0.9)
ORR, % (95% CI)
CR + PR	44.1 (37.6 to 50.8)	21.6 (16.4 to 27.4)
Difference in ORR	22.3 (14.0 to 30.6); nominal P < .0001
DoR, months
Median (95% CI)	4.1 (3.1 to 4.3)	4.2 (2.9 to 4.8)

Abbreviations: CR, complete response; DoR, duration of response; ORR, objective response rate; PR, partial response.